May 9, 2024 11:06 AM EDT

Royalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher

ENDPOINTS

Plus, news about Pacira Biosciences, Cassava Sciences, Merck, Monopar Therapeutics, Eli Lilly and Optinose:

Royalty Pharma signs MS deal: The company will pay about $525 million in cash to buy the milestones and royalties that ImmuNext is set to receive from Sanofi for a Phase 3 multiple sclerosis drug. Sanofi is expected to seek FDA approval of the monoclonal antibody in 2027. If frexalimab is approved, Royalty expects to get royalties from the drug through 2041. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Royalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher

ENDPOINTS

Unlock this article instantly by becoming a free subscriber.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

Rapport, a clinical-stage neuroscience biotech, files for IPO

AstraZeneca earmarks $1.5B for end-to-end ADC factory in Singapore

Gilead's rare liver disease drug improves symptoms in another Phase 3 study ahead of FDA decision

FDA rejects liver cancer drug combo, shares of Korean biotech tank

Study identifies groups of people who mistrust the FDA

Back to the future: From target-selective drug design to AI-enabled polypharmacology

Roy­al­ty Phar­ma inks MS deal with Im­muNext; X4 sells its pri­or­i­ty re­view vouch­er

Unlock this article instantly by becoming a free subscriber.

Celldex Therapeutics

Hampton, NJ, USA

Royalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher